Wemodel theeventofinterest asaspecial terminal state, andwe seek to estimate the survival distribution (i.e., the distribution of the hitting time for that terminal state) from anyother state.

This method effectively improves the model's marginal and conditional calibration,

Quantifying out-of-sample discrimination performance for time-to-event outcomes is a fundamental step for model evaluation and selection in the context of predictive modelling. The concordance index, or C-index, is a widely used metric for this purpose, particularly with the growing development of machine learning methods. Beyond differences between proposed C-index estimators (e.g. Harrell's, Uno's and Antolini's), we demonstrate the existence of a C-index multiverse among available R and python software, where seemingly equal implementations can yield different results. This can undermine reproducibility and complicate fair comparisons across models and studies. Key variation sources include tie handling and adjustment to censoring. Additionally, the absence of a standardised approach to summarise risk from survival distributions, result in another source of variation dependent on input types. We demonstrate the consequences of the C-index multiverse when quantifying predictive performance for several survival models (from Cox proportional hazards to recent deep learning approaches) on publicly available breast cancer data, and semi-synthetic examples. Our work emphasises the need for better reporting to improve transparency and reproducibility. This article aims to be a useful guideline, helping analysts when navigating the multiverse, providing unified documentation and highlighting potential pitfalls of existing software. All code is publicly available at: www.github.com/BBolosSierra/CindexMultiverse.

Survival prediction often involves estimating the time-to-event distribution from censored datasets. Previous approaches have focused on enhancing discrimination and marginal calibration. In this paper, we highlight the significance of conditional calibration for real-world applications -- especially its role in individual decision-making. We propose a method based on conformal prediction that uses the model's predicted individual survival probability at that instance's observed time. This method effectively improves the model's marginal and conditional calibration, without compromising discrimination. We provide asymptotic theoretical guarantees for both marginal and conditional calibration and test it extensively across 15 diverse real-world datasets, demonstrating the method's practical effectiveness and versatility in various settings.

Given an instance, a multi-event survival model predicts the time until that instance experiences each of several different events. These events are not mutually exclusive and there are often statistical dependencies between them. There are relatively few multi-event survival results, most focusing on producing a simple risk score, rather than the time-to-event itself. To overcome these issues, we introduce MENSA, a novel, deep learning approach for multi-event survival analysis that can jointly learn representations of the input covariates and the dependence structure between events. As a practical motivation for multi-event survival analysis, we consider the problem of predicting the time until a patient with amyotrophic lateral sclerosis (ALS) loses various physical functions, i.e., the ability to speak, swallow, write, or walk. When estimating when a patient is no longer able to swallow, our approach achieves an L1-Margin loss of 278.8 days, compared to 355.2 days when modeling each event separately. In addition, we also evaluate our approach in single-event and competing risk scenarios by modeling the censoring and event distributions as equal contributing factors in the optimization process, and show that our approach performs well across multiple benchmark datasets. The source code is available at: https://github.com/thecml/mensa

Identifying patient subgroups with different treatment responses is an important task to inform medical recommendations, guidelines, and the design of future clinical trials. Existing approaches for subgroup analysis primarily focus on Randomised Controlled Trials (RCTs), in which treatment assignment is randomised. Furthermore, the patient cohort of an RCT is often constrained by cost, and is not representative of the heterogeneity of patients likely to receive treatment in real-world clinical practice. Therefore, when applied to observational studies, such approaches suffer from significant statistical biases because of the non-randomisation of treatment. Our work introduces a novel, outcome-guided method for identifying treatment response subgroups in observational studies. Our approach assigns each patient to a subgroup associated with two time-to-event distributions: one under treatment and one under control regime. It hence positions itself in between individualised and average treatment effect estimation. The assumptions of our model result in a simple correction of the statistical bias from treatment non-randomisation through inverse propensity weighting. In experiments, our approach significantly outperforms the current state-of-the-art method for outcome-guided subgroup analysis in both randomised and observational treatment regimes.

Survival Analysis provides critical insights for partially incomplete time-to-event data in various domains. It is also an important example of probabilistic machine learning. The probabilistic nature of the predictions can be exploited by using (proper) scoring rules in the model fitting process instead of likelihood-based optimization. Our proposal does so in a generic manner and can be used for a variety of model classes. We establish different parametric and non-parametric sub-frameworks that allow different degrees of flexibility. Incorporated into neural networks, it leads to a computationally efficient and scalable optimization routine, yielding state-of-the-art predictive performance. Finally, we show that using our framework, we can recover various parametric models and demonstrate that optimization works equally well when compared to likelihood-based methods.

An accurate model of patient survival time can help in the treatment and care of cancer patients. The common practice of providing survival time estimates based only on population averages for the site and stage of cancer ignores many important individual differences among patients. In this paper, we propose a local regression method for learning patient-specific survival time distribution based on patient attributes such as blood tests and clinical assessments. When tested on a cohort of more than 2000 cancer patients, our method gives survival time predictions that are much more accurate than popular survival analysis models such as the Cox and Aalen regression models. Our results also show that using patient-specific attributes can reduce the prediction error on survival time by as much as 20% when compared to using cancer site and stage only.